Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

FRAME: A Phase I Trial of the Combination of Defactinib (VS-6063) (FAK Inhibitor) and VS-6766 (RO5126766) (CH5126776) (a Dual RAF/MEK Inhibitor) in Patients With Advanced Solid Tumours

NCT03875820 is registered in ClinicalTrials.gov with Institute of Cancer Research, United Kingdom as lead sponsor.

NCT NCT03875820
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03875820 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
FRAME: A Phase I Trial of the Combination of Defactinib (VS-6063) (FAK Inhibitor) and VS-6766 (RO5126766) (CH5126776) (a Dual RAF/MEK Inhibitor) in Patients With Advanced Solid Tumours
Lead sponsor
Institute of Cancer Research, United Kingdom
Phase
Phase 1
Overall status
Active, not recruiting
Start date
December 12, 2017
Completion date
October 31, 2026
Enrollment
87 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

endometrioid carcinoma, low grade serous ovarian cancer, nsclc, pancreatic cancer